Artiva Biotherapeutics

ARTVNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$395.521 M

$8.09 +3.32%

Close of 22 Sept 2026

Revenue

$0.00

#3637 by revenue

Earnings

-$83.9M

Loss-making

Shares outstanding

48,890,121

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#74Cabaletta BioCABA$423.9M
#75C4 TherapeuticsCCCC$407.2M
#76Artiva BiotherapeuticsARTV$395.5M
#77AgenusAGEN$392.9M
#78Fennec PharmaceuticalsFENC$385.7M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Artiva Biotherapeutics, worth $868.5K. Grants and option exercises are excluded.

Peter Kolchinsky, RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., RA Capital Nexus Fund, L.P., Rajeev M. Shah$455.7K
45,768 shares at $9.96 on 29 Jul 2026 · filed 31 Jul 2026
Peter Kolchinsky, RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., RA Capital Nexus Fund, L.P., Rajeev M. Shah$412.8K
41,319 shares at $9.99 on 24 Jul 2026 · filed 28 Jul 2026

What if Artiva Biotherapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$618,406.52

Per share 76,441× higher

Bitcoin $1.74T

$35,623.86

Per share 4,403× higher

Nvidia $5.52T

$112,819.66

Per share 13,946× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Artiva Biotherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.